FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890318265> ?p ?o ?g. }

• W2890318265 endingPage "3910" @default.
• W2890318265 startingPage "3891" @default.
• W2890318265 abstract "First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis Kang-Kang Chen,1 Tai-Feng Du,1 Ku-Sheng Wu,2 Wei Yang3 1Department of Preventive Medicine and MPH Education Center, Shantou University Medical College, Shantou, Guangdong Province, China; 2Department of Preventive Medicine, Shantou University Medical College, Shantou, Guangdong Province, China; 3Department of Thoracic Surgery, Administrative Office, Shantou University Medical College Cancer Hospital, Shantou, Guangdong Province, China Objectives: With bosutinib proven to be available for frontline treatment, there are currently four frontline treatments as well as an additional strategy with high-dose imatinib for newly diagnosed chronic myeloid leukemia (CML). Due to the lack of direct comparison of high-dose imatinib, dasatinib, nilotinib, and bosutinib, we summarized the evidence to indirectly compare the efficacy among these treatment options.Methods: In total, 14 randomized clinical trials including 5,630 patients were analyzed by direct and mixed-treatment comparisons. Outcomes assessed were the following: complete cytogenetic response at 12 months; major molecular response at 12, 24, and 36 months; deep molecular response at 12, 24, 36, and 60 months; early molecular response at 3 months; progression-free survival (PFS); overall survival (OS); and Grade 3 or 4 adverse events (AEs).Results: The Bayesian network meta-analysis demonstrated that high-dose imatinib was less effective than all new-generation tyrosine kinase inhibitors and had a higher probability of Grade 3 or 4 AEs. For molecular response, 300 mg of nilotinib was likely to be the preferred frontline treatment, as demonstrated by higher response rates and faster, deeper, and longer molecular response. For PFS and OS, there were high likelihoods (79% and 74%, respectively) that 400 mg of nilotinib was the preferred option. For AEs, standard-dose imatinib has the highest probability (65%) of being the most favorable toxicity profile.Conclusion: Considering the efficacy and toxicity profile, it is not recommended to use high-dose imatinib for treatment. This analysis also showed that nilotinib has the highest probability to become the preferred frontline agents for treating CML. Keywords: CML, tyrosine kinase inhibitor, imatinib, bosutinib, dasatinib, nilotinib" @default.
• W2890318265 created "2018-09-27" @default.
• W2890318265 creator A5006388743 @default.
• W2890318265 creator A5006937743 @default.
• W2890318265 creator A5014899743 @default.
• W2890318265 creator A5091400560 @default.
• W2890318265 date "2018-09-01" @default.
• W2890318265 modified "2023-10-16" @default.
• W2890318265 title "First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis" @default.
• W2890318265 cites W122973089 @default.
• W2890318265 cites W1430390330 @default.
• W2890318265 cites W1527252739 @default.
• W2890318265 cites W1968232397 @default.
• W2890318265 cites W1968747503 @default.
• W2890318265 cites W2009972868 @default.
• W2890318265 cites W2010678043 @default.
• W2890318265 cites W2011186694 @default.
• W2890318265 cites W2012828386 @default.
• W2890318265 cites W2014839361 @default.
• W2890318265 cites W2016960626 @default.
• W2890318265 cites W2021648831 @default.
• W2890318265 cites W2027744772 @default.
• W2890318265 cites W2028959752 @default.
• W2890318265 cites W2032531836 @default.
• W2890318265 cites W2034469570 @default.
• W2890318265 cites W2052054991 @default.
• W2890318265 cites W2057827171 @default.
• W2890318265 cites W2058216377 @default.
• W2890318265 cites W2064130198 @default.
• W2890318265 cites W2070507117 @default.
• W2890318265 cites W2088095316 @default.
• W2890318265 cites W2097799776 @default.
• W2890318265 cites W2098923148 @default.
• W2890318265 cites W2106392592 @default.
• W2890318265 cites W2119900325 @default.
• W2890318265 cites W2143939343 @default.
• W2890318265 cites W2156145496 @default.
• W2890318265 cites W2164702101 @default.
• W2890318265 cites W2172189430 @default.
• W2890318265 cites W2230151041 @default.
• W2890318265 cites W2260921597 @default.
• W2890318265 cites W2313607879 @default.
• W2890318265 cites W2322365534 @default.
• W2890318265 cites W2343861412 @default.
• W2890318265 cites W2345930365 @default.
• W2890318265 cites W2378200925 @default.
• W2890318265 cites W2518220782 @default.
• W2890318265 cites W2556518969 @default.
• W2890318265 cites W2560342075 @default.
• W2890318265 cites W2570618306 @default.
• W2890318265 cites W2588681363 @default.
• W2890318265 cites W2590307110 @default.
• W2890318265 cites W2592060299 @default.
• W2890318265 cites W2764011156 @default.
• W2890318265 cites W2766187515 @default.
• W2890318265 cites W2774495789 @default.
• W2890318265 cites W2793387867 @default.
• W2890318265 doi "https://doi.org/10.2147/cmar.s177566" @default.
• W2890318265 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6163008" @default.
• W2890318265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30288121" @default.
• W2890318265 hasPublicationYear "2018" @default.
• W2890318265 type Work @default.
• W2890318265 sameAs 2890318265 @default.
• W2890318265 citedByCount "9" @default.
• W2890318265 countsByYear W28903182652019 @default.
• W2890318265 countsByYear W28903182652020 @default.
• W2890318265 countsByYear W28903182652021 @default.
• W2890318265 countsByYear W28903182652022 @default.
• W2890318265 crossrefType "journal-article" @default.
• W2890318265 hasAuthorship W2890318265A5006388743 @default.
• W2890318265 hasAuthorship W2890318265A5006937743 @default.
• W2890318265 hasAuthorship W2890318265A5014899743 @default.
• W2890318265 hasAuthorship W2890318265A5091400560 @default.
• W2890318265 hasBestOaLocation W28903182651 @default.
• W2890318265 hasConcept C126322002 @default.
• W2890318265 hasConcept C143998085 @default.
• W2890318265 hasConcept C197934379 @default.
• W2890318265 hasConcept C2777413986 @default.
• W2890318265 hasConcept C2777583451 @default.
• W2890318265 hasConcept C2778208673 @default.
• W2890318265 hasConcept C2778729363 @default.
• W2890318265 hasConcept C2779536868 @default.
• W2890318265 hasConcept C71924100 @default.
• W2890318265 hasConcept C95190672 @default.
• W2890318265 hasConceptScore W2890318265C126322002 @default.
• W2890318265 hasConceptScore W2890318265C143998085 @default.
• W2890318265 hasConceptScore W2890318265C197934379 @default.
• W2890318265 hasConceptScore W2890318265C2777413986 @default.
• W2890318265 hasConceptScore W2890318265C2777583451 @default.
• W2890318265 hasConceptScore W2890318265C2778208673 @default.
• W2890318265 hasConceptScore W2890318265C2778729363 @default.
• W2890318265 hasConceptScore W2890318265C2779536868 @default.
• W2890318265 hasConceptScore W2890318265C71924100 @default.
• W2890318265 hasConceptScore W2890318265C95190672 @default.
• W2890318265 hasLocation W28903182651 @default.
• W2890318265 hasLocation W28903182652 @default.
• W2890318265 hasLocation W28903182653 @default.
• W2890318265 hasLocation W28903182654 @default.

• next